{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:09:07Z","timestamp":1790276947373,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Starpharma Pty Ltd."},{"name":"Astodrimer Gel"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ejogrb.2019.11.032","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T13:01:17Z","timestamp":1574946077000},"page":"13-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis"],"prefix":"10.1016","volume":"245","author":[{"given":"Steven E.","family":"Chavoustie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belvia A.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur S.","family":"Waldbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert G.G.","family":"Donders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus H.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane R.","family":"Schwebke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9981-421X","authenticated-orcid":false,"given":"Jeremy R.A.","family":"Paull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare F.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Castellarnau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"McCloud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Kinghorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.ejogrb.2019.11.032_bib0005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/infdis\/jiw121","article-title":"Pathogenesis of bacterial vaginosis: discussion of current hypotheses","volume":"214","author":"Muzny","year":"2016","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.ejogrb.2019.11.032_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074378","article-title":"The burden of bacterial vaginosis: women\u2019s experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis","volume":"8","author":"Bilardi","year":"2013","journal-title":"PLoS One"},{"issue":"RR-03","key":"10.1016\/j.ejogrb.2019.11.032_bib0015","first-page":"1","article-title":"Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines","volume":"64","author":"Workowski","year":"2015","journal-title":"MMWR"},{"issue":"13","key":"10.1016\/j.ejogrb.2019.11.032_bib0020","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1177\/0956462418785451","article-title":"2018 European (IUSTI\/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge","volume":"29","author":"Sherrard","year":"2018","journal-title":"Intl J STD AIDS."},{"key":"10.1016\/j.ejogrb.2019.11.032_bib0025","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1086\/509577","article-title":"A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis","volume":"44","author":"Schwebke","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ejogrb.2019.11.032_bib0030","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1086\/503780","article-title":"High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence","volume":"193","author":"Bradshaw","year":"2006","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ejogrb.2019.11.032_bib0035","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1093\/infdis\/jiw159","article-title":"Current treatment of bacterial vaginosis - Limitations and need for innovation","volume":"214","author":"Bradshaw","year":"2016","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.ejogrb.2019.11.032_bib0040","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1517\/14656566.2014.881800","article-title":"Treatment of bacterial vaginosis: what we have and what we miss","volume":"15","author":"Donders","year":"2014","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.ejogrb.2019.11.032_bib0045","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/OLQ.0b013e3181bc0aac","article-title":"Safety, tolerability, and pharmacokinetics of SPL7013 Gel (VivaGel\u00ae): A dose ranging, phase I study","volume":"37","author":"O\u2019Loughlin","year":"2010","journal-title":"Sex Transm Dis"},{"issue":"8","key":"10.1016\/j.ejogrb.2019.11.032_bib0050","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/QAD.0b013e328346bd3e","article-title":"Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 Gel (VivaGel\u00ae) in sexually active young women (MTN-004)","volume":"25","author":"McGowan","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.ejogrb.2019.11.032_bib0055","article-title":"A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose-ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis","author":"Waldbaum","year":"2019","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.ejogrb.2019.11.032_bib0060","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1089\/aid.2005.21.845","article-title":"In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials","volume":"21","author":"Tien","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"10.1016\/j.ejogrb.2019.11.032_bib0065","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.contraception.2006.09.003","article-title":"Fourteen-day safety and acceptability study of the universal placebo gel","volume":"75","author":"Schwartz","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.ejogrb.2019.11.032_bib0070","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0002-9343(83)91112-9","article-title":"Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations","volume":"74","author":"Amsel","year":"1983","journal-title":"Am J Med"},{"key":"10.1016\/j.ejogrb.2019.11.032_bib0075","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1128\/jcm.29.2.297-301.1991","article-title":"Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation","volume":"29","author":"Nugent","year":"1991","journal-title":"J Clin Microbiol"},{"issue":"12","key":"10.1016\/j.ejogrb.2019.11.032_bib0080","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/OLQ.0b013e3181fbbc95","article-title":"Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS\/NIH\/NIAID","volume":"37","author":"Marrazzo","year":"2010","journal-title":"Sex Transm Dis"},{"issue":"678","key":"10.1016\/j.ejogrb.2019.11.032_bib0085","first-page":"e1","article-title":"A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis","volume":"217","author":"Schwebke","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ejogrb.2019.11.032_bib0090","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/LGT.0000000000000062","article-title":"Metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis: a doseranging study","volume":"19","author":"Chavoustie","year":"2015","journal-title":"J Low Genit Tract Dis"},{"issue":"2","key":"10.1016\/j.ejogrb.2019.11.032_bib0095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11908-009-0021-7","article-title":"New concepts in the etiology of bacterial vaginosis","volume":"11","author":"Schwebke","year":"2009","journal-title":"Curr Infect Dis Rep"},{"issue":"6","key":"10.1016\/j.ejogrb.2019.11.032_bib0100","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ajog.2019.10.087","article-title":"Results of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Astodrimer Gel for prevention of recurrent bacterial vaginosis","volume":"221","author":"Schwebke","year":"2019","journal-title":"Am J Obstet Gynecol"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211519305470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211519305470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:45:49Z","timestamp":1759556749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211519305470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":20,"alternative-id":["S0301211519305470"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2019.11.032","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2019.11.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}